Skip to Main Content

WASHINGTON — The Trump administration has proposed modest steps this year to promote biosimilar and generic medications, but each proposal has been met with staunch opposition from nearly all corners of the health care industry.

The proposals are small and wonky: Under one, bonuses for insurers would be partially determined based on how often they encourage patients to use generic drugs; under another, insurers would be able to push patients toward lower-cost medicines by creating a new “tier” of medicines in their plan designs. And yet these proposals were lambasted in recent comments filed with the federal government as risky, inappropriate, and counterproductive.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED